Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Other Nonoperating Income Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — other nonoperating income expense of -$162K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense decreased by 361.3% year-over-year, from $62K to -$162K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — other nonoperating income expense has grown at a 8.7% compound annual growth rate (CAGR), from -$1.25M to -$1.47M.
- What does gyre pharmaceuticals — other nonoperating income expense mean?
- This includes income or expenses that fall outside the scope of the segment's primary business operations, such as foreign exchange fluctuations or miscellaneous financial items. It is used to identify peripheral financial impacts that do not reflect the core performance of the pharmaceutical business.